BioXcel Therapeutics announces $60M common stock offering

BioXcel Therapeutics announced that it has commenced an underwritten public offering of $60M of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. All of the securities to be sold in the offering are being sold by the company. The company intends to use the net proceeds of this offering to fund ongoing and planned clinical trials, commercialization and general corporate purposes. BofA Securities and Truist Securities are acting as joint book-running managers for the proposed public offering.